Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| King's College Hospital NHS Trust | OTHER |
Not provided
Not provided
Not provided
Not provided
This study aims to find out whether an adapted version of an existing cognitive rehabilitation program, CIRCuiTS (https://www.circuitstherapyinfo.com), can be used to improve everyday thinking skills for people with Multiple Sclerosis (MS). People living with MS have worked with the study's researchers to adapt CIRCuiTS to meet their needs. They shared the thinking challenges they experience and suggested changes to the program's content and how it is delivered. This study will test whether this adapted version can be delivered practically to people with MS in a trial setting and explore its potential benefits. The findings will help plan a larger trial testing how effective CIRCuiTS is in helping people with MS.
Twenty-four people with MS will take part in this pilot trial. Each person will be randomly assigned to start the program either right away or after a 13-week wait. The therapy program involves up to 36 hours of therapist-led and independent sessions over 12 weeks in which the participant builds thinking skills through developing personal strategies for carrying out digital versions of tasks they find challenging. The practicality of delivering the program to people with MS will be judged based on whether problems arise in the trial, such as not being able to recruit enough people or participants not liking it. To explore its potential benefits, the study will check for improvements in progress toward personal goals, thinking abilities, emotional well-being, chronic tiredness, and daily living skills after the therapy.
If delivering CIRCuiTS to people with MS is found to be both practical and acceptable to participants, the findings of this trial will be used to design a larger-scale trial of its effectiveness. Ultimately, the goal of this project is to improve the quality of life of people living with cognitive difficulties related to MS.
Objectives
The primary goal of this study is to assess the practical aspects of the research to determine whether a larger, fully-scale trial will be viable and acceptable. A feasibility decision will be reached by judging whether a suite of "Go"/"No-Go" thresholds associated with the primary outcome measures have been passed. Additionally, acceptability will be explored through qualitative analysis of participant exit interviews.
The secondary goal is to explore the potential that a larger trial will show that the program helps people with MS in meaningful ways.
Specifically, the study will examine whether the cognitive remediation program:
These factors will be evaluated through assessing change in the secondary outcome measures after therapy.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Immediate Treatment Group | Experimental | Participants will start the cognitive remediation program immediately after recruitment. Outcome measures will be taken before treatment (week 1), immediately after treatment (week 14), and at 14 weeks after end of treatment (week 27). |
|
| Delayed Treatment Group | Experimental | Participants will start the cognitive remediation program after being on a waitlist for 13 weeks. Outcome measures will be taken when added to the waitlist (week 1), before treatment (week 14), and immediately after treatment (week 27). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CIRCuiTS-MS | Behavioral | The intervention is a blended treatment combining therapist support with carrying out tasks in CIRCuiTS™ digital cognitive remediation software. This software provides opportunities to practice a range of cognitive tasks and adaptively adjusts task difficulty. CIRCuiTS™ is much used in psychosis. Based on collaborative workshops with people with MS, participants for this trial will be asked to attend two 1-hour therapy sessions (in person or on MS Teams) and 1 hour of independent tasks each week for 12 weeks. Participants with reduced ability to operate a mouse quickly or dexterously will be offered a modified programme omitting tasks that require these abilities. The therapist will be an Assistant Psychologist trained in CIRCuiTS™ delivery and in appropriate adjustments to the needs of people with MS. They will follow a manualised template and will receive weekly supervision from an experienced clinical psychologist. |
| Measure | Description | Time Frame |
|---|---|---|
| Recruitment rate | Percentage of planned sample size recruited | Until the end of the study, estimated 15 months |
| Ethnic enrolment diversity | Percentage of sample belonging to the most common ethnicity | Until the end of the study, estimated 15 months |
| Gender enrolment diversity | Difference in the percentages of recruited participants identifying as male and female | Until the end of the study, estimated 15 months |
| Completion rate | Percentage of participants completing week 27 measures | Until the end of the study, estimated 15 months |
| Midpoint retention | Percentage of participants completing week 14 measures | Until the end of the study, estimated 15 months |
| Dropout | Percentage of enrolled participants who drop out | Until the end of the study, estimated 15 months |
| Serious adverse events | Number of serious adverse events reported | Until the end of the study, estimated 15 months |
| Manageability of adverse events | Number of adverse events that cause the study to be halted |
| Measure | Description | Time Frame |
|---|---|---|
| Goal Attainment Scale | A personalised measure used to assess the extent to which patient-specific goals are achieved during therapy. Goals are collaboratively set between the therapist and patient, and the level of attainment is rated on a scale typically ranging from -2 (much less than expected outcome) to +2 (much more than expected outcome). | From goal setting in week 1 to week 27 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sara Simblett, PhD | King's College London | Principal Investigator |
| Til Wykes, PhD | King's College London | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| King's College London | London | East of England | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42321924 | Derived | Thomas RJ, Cella M, Brex PA, Silber E, Fifield K, Burke P, Summers M, Simblett S, Wykes T. Co-development of a protocol for a randomised controlled feasibility trial of CIRCuiTS cognitive remediation therapy for people with multiple sclerosis. Pilot Feasibility Stud. 2026 Jun 20. doi: 10.1186/s40814-026-01862-2. Online ahead of print. |
| Label | URL |
|---|---|
| Website introducing the CIRCuiTS intervention | View source |
Not provided
De-identified text-based participant data and a data dictionary describing the data types collected will be provided.
Available from the end of analysis (anticipated September 2026).
Data and supporting information will be shared upon application to the listed study team.
Not provided
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| D060825 | Cognitive Dysfunction |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
Participants will be randomly assigned to one of two groups:
Not provided
Not provided
Not provided
|
| Until the end of the study, estimated 15 months |
| Data completeness | Percentage outcome data complete | Until the end of the study, estimated 15 months |
| Specific measure completeness | Percentage outcome data complete per measure | Until the end of the study, estimated 15 months |
| Operational feasibility | Number of significant operational issues that cannot be resolved | Until the end of the study, estimated 15 months |
| Adherence: Therapy | Percentage participants attending ≥ 70% of therapy sessions | Until the end of the study, estimated 15 months |
| Adherence: Independent sessions | Percentage participants attending ≥ 40% of therapy sessions | Until the end of the study, estimated 15 months |
| Specific measure acceptability | Percentage of participants who provide answers to demographic/medical background questions | Until the end of the study, estimated 15 months |
| Program acceptability | Mean score on the general acceptability item of the Theoretical Framework of Acceptability Questionnaire | Until the end of the study, estimated 15 months |
| Measure of Insight into Cognition | A self-report questionnaire designed to assess an individual's awareness and understanding of their cognitive abilities and deficits. It is particularly useful in clinical settings where cognitive impairments are common, such as in MS. The MIC consists of a series of statements that participants rate based on their perception of their cognitive functions. Each item is rated on a Likert scale, ranging from 1 to 5, from strongly agree to strongly disagree. The total score is the sum or average of the scores for the items. Higher scores indicate greater insight into one's cognitive abilities and deficits. | From baseline assessment at week 1 to week 27 |
| Brief International Cognitive Assessment for Multiple Sclerosis | Designed for rapid assessment of neuropsychological abilities commonly affected in MS. Comprises: The Symbol Digit Modalities Test, measuring processing speed and attention. The participant is asked to orally identify the digits associated with test symbols within a key. It is scored on the number of digits correctly identified within 90 seconds. Tasks 1-3 of the Brief Visuospatial Memory Test, measuring immediate visual recall. The participant inspects an array of 6 abstract geometric figures during three 10-second learning trials and then draws the array from memory. Higher scores are awarded for more accurate figure reproduction and positioning. Tasks 1-5 of the California Verbal Learning Test-Second Edition, measuring verbal working memory. The rater reads a 16-item word list aloud five times to the participant, who is then required to recall as many as possible. | From baseline assessment at week 1 to week 27 |
| Digit Span | This subtest from the Wechsler Adult Intelligence Scale Version 4 will be administered because it is a widely used measure of attention and working memory that does not show strong correlations with the California Verbal Learning Test. The participants is required to repeat sequences of digits, proceeding to longer sequences if correct, then repeat sequences backwards and in numerical order. | From baseline assessment at week 1 to week 27 |
| Controlled Oral Word Association Test | A widely used neuropsychological assessment tool designed to measure verbal fluency, a component of executive function. It assesses the ability to generate words according to specific phonemic and semantic criteria within a limited time frame. The COWAT is commonly used in the diagnosis and evaluation of various neurological and psychiatric conditions. To measure phonemic fluency, participants are asked to produce as many words as possible that begin with a specific letter (usually F, A, and S) within 60 seconds for each letter. To measure semantic fluency, participants are asked to produce as many words as possible within a category (e.g., animals) within 60 seconds. The number of correct words generated in each category (phonemic and semantic) is counted. Repetitions, proper nouns, and variations of the same word are not included in the score. Errors will also be analysed, such as repetitions or rule violations, providing additional insights into cognitive function. | From baseline assessment at week 1 to week 27 |
| Patient Health Questionnaire-9 | A widely used self-administered tool for screening, diagnosing, monitoring, and measuring the severity of depression. It is based on the diagnostic criteria for major depressive disorder outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). The PHQ-9 consists of 9 items, each corresponding to one of the DSM-IV criteria for depression. Each item is rated on a 4-point Likert scale based on the frequency of symptoms over the past two weeks. The total score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms. | From baseline assessment at week 1 to week 27 |
| Generalised Anxiety Disorder Scale | A brief, self-report screening tool commonly used in clinical and research settings to assess the severity of generalised anxiety disorder (GAD) symptoms. The GAD-7 provides an efficient way to identify GAD symptoms and track their severity over time. The GAD-7 contains 7 questions that evaluate the frequency of core anxiety symptoms over the past two weeks. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. | From baseline assessment at week 1 to week 27 |
| Fatigue Severity Scale | A self-report questionnaire designed to assess the impact of fatigue on a person's daily life. It is widely used in clinical and research settings to evaluate fatigue in various conditions, including multiple sclerosis (MS). The FSS consists of 9 statements related to the severity and impact of fatigue. Each item is rated on a 7-point Likert scale. The total score is the average of the scores for the 9 items, resulting in a score range from 1 to 7. Higher scores indicate greater fatigue severity and impact. | From baseline assessment at week 1 to week 27 |
| Work and Social Adjustment Scale | A self-report questionnaire designed to assess the impact of a person's mental health on their daily functioning. It is widely used in both clinical and research settings to gauge the extent to which psychological problems interfere with a person's ability to perform various life roles. The WSAS consists of 5 items, corresponding to five domains of daily functioning: work, home management, social leisure activities, private leisure activities, and family and relationships. Each item is rated on an 8-point Likert scale from 0 (not at all impaired) to 8 (severely impaired). The total score is the sum of the ratings for the five items, resulting in a score range from 0 to 40. Higher scores indicate greater impairment. A total score of 20 or above suggests significant functional impairment. | From baseline assessment at week 1 to week 27 |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |